Elton Jeffrey North, BS, MS, PhD

Department

Pharmacy Sciences

Position

Associate Professor

Books

• E. Jeffrey North. Chapter 15 - Drugs Used to Treat Pain: Peripherally Active Agents. In Foye’s Principles of Medicinal Chemistry
  8th Ed. 2019
• Elmer Gentry, E. Jeffrey North, Robin Zavod, Chapter 29 - Drugs Used to Treat Bacterial Infections.  In Foye’s Principles of Medicinal Chemistry
  8th Ed. 2019

Articles

• AAPS PharmSciTech
  S. Deodhar, A. K. Dash, E. J. North, M. Hulce, S. Deodhar, A. K. Dash, E. J. North, M. Hulce, Development and In Vitro Evaluation of Long Circulating Liposomesfor Targeted Delivery of Gemcitabine and Irinotecan in Pancreatic Ductal Adenocarcinoma, AAPS PharmaSciTech, 2020, 21, 231 2020
• International Journal of Molecular Sciences
  Jigar P. Sethiya, Melanie A. Sowards, Mary Jackson, E. Jeffrey North, Jigar P. Sethiya, Melanie A. Sowards, Mary Jackson, E. Jeffrey North, MmpL3 Inhibition: A New Approach to Treat Nontuberculous Mycobacterial Infections, International Journal of Molecular Sciences, 2020, 21(17), 6202. 2020
• ACS Infectious Diseases
  W. Li, C.M. Stevens, A.N. Pandya, Z. Darzynkiewicz, P. Bhattarai, W. Tong, M. Gonzalez-Juarrero, E.J. North, H.I. Zqurskaya, M. Jackson, Direct Inhibition of MmpL3 by Novel Antitubercular Compounds
  5(6), p. 1001-1012 2019
• AAPS PharmSciTech
  A. Gumireddy, R. Christman, D. Kumari, A. Tiwari, E.J. North, H. Chauhan, Preparation, Characterization, and In vitro Evaluation of Curcumin- and Resveratrol-Loaded Solid Lipid Nanoparticles
  20(4) 2019
• Antimicrobial Agents and Chemotherapy
  A.N. Pandya, P.K. Prathipati, P. Hegde, W. Li, K.F. Graham, S. Mandal, K.M. Drescher, C.J. Destache, D. Ordway, M. Jackson, E.J. North, Indole-2-carboxamides are Active Against an Acute Mycobacterium abscessus Infected Mouse Model
  [Epub ahead of print] 2019
• Frontiers in Microbiology
  W. Li, A. Yazidi, A.N. Pandya, P. Hegde, W. Tong, V. Calado Nogueira de Moura, E.J. North, J. Sygusch, M. Jackson, MmpL3 as a Target for the Treatment of Drug-Resistant Nontuberculous Mycobacterial Infections
  9, p. 1547 2018
• Bioorganic & Medicinal Chemistry
  N.D. Franz, J.M. Belardinelli, M.A. Kaminski, L.C. Dunn, V. Calado Nogueira de Moura, M.A. Blaha, D.D. Truong, W. Li, M. Jackson, E.J. North, Design, synthesis and evaluation of indole-2-carboxamides with pan anti-mycobacterial activity
  25(14), p. 3746-3755 2017
• Tetrahedron Letters
  A.N. Pandya, E.M. Villa, E.J. North, A simple and efficient approach for the synthesis of 2-aminated quinazoline derivatives via metal free oxidative annulation
  58(13), p. 1276-1279 2017
• Antimicrobial Agents and Chemotherapy
  W. Li, A. Sanchez-Hidalgo, V. Jones, V. Calado Nogueira de Moura, E.J. North, M. Jackson, Synergistic interactions of MmpL3 inhibitors with antitubercular compounds in vitro
  61(4), p. e02399-16 2017
• Antimicrobial Agents and Chemotherapy
  W. Li, A. Obregon-Henao, J.B. Wallach, E.J. North, R.E. Lee, M. Gonzalez-Juarrero, D. Schnappinger, M. Jackson
  60(9), p. 5198-5207 2016
• ASSAY and Drug Development Technologies
  S.I. Farah, A.A. Abdelrahman, E. Jeffrey North, H. Chauhan, Opportunities and Challenges for Natural Products as Novel Antituberculosis Agents
  14(1), p. 29-38 2016
• ACS Infectious Diseases
  A.E. Grzegorzwicz, N. Eynard, A. Quemard, E. Jeffrey North, A. Margolis, J.J. Lindenberger, V. Jones, J. Kordulakova, P.J. Brennan, R.E. Lee, D.R. Ronning, M.R. McNeil, M. Jackson, Covalent Modification of the Mycobacterium tuberculosis FAS-II dehydratase by Isoxyl and Thiacetazone
  1(2), p. 91-97 2015
• Antimicrobial Agents and Chemotherapy
  W. Li, A. Upadhyay, F.L. Fontes, E. Jeffrey North, Y. Wang, D.C. Crans, A.E. Grzegorzewicz, V. Jones, S.G. Franzblau, R.E. Lee, D.C. Crick, M. Jackson, Novel Insights into the Mechanism of Inhibition of MmpL3, a Target of Multiple Pharmacophores in Mycobacterium tuberculosis
  58(11), p. 6413-6423 2014
• Antimicrobial Agents and Chemotherapy
  Ekaterina Gavrish, Binu Shrestha, Chao Chen, Ida Lister, E. Jeffrey North, Lei Yang, Richard E. Lee, Angel Han, Bronwyn Williams, David Chamuska, Ken Coleman, Kim Lewis, Michael LaFleur, In vitro and in vivo Activity of HPi1, a Selective Antimicrobial against Helicobacter pylori
  58(6), p. 3255-3260 2014
• Antimicrobial Agents and Chemotherapy
  Laura Fleck, E. Jeffrey North, Richard Lee, Lawrence Mulcaha, Gabriele Casadei, Kim Lewis, A Screen and Validation of Prodrug Antimicrobials
  58(3), p. 1410-1419 2014
• Current Pharmaceutical Design
  E. Jeffrey North, Mary Jackson, Richard E. Lee, New Approaches to Target the Mycolic Acid Biosynthesis Pathway
  20(27), p. 4357-78 2014
• Antimicrobial Agents and Chemotherapy
  Michael LaFleur, Lingmei Sun, Ida Lister, John Keating, Andra Nantel, Lisa Long, Mahmoud Ghannoum, Jeffrey North, Richard Lee, Ken Coleman, Thomas Dahl, Kim Lewis, Potentiation of azole antifungals by 2-adamantanamine
  57(8), p. 3585-3592 2013
• Bioorganic & Medicinal Chemistry
  E. Jeffrey North, Michael S. Scherman, David F. Bruhn, Jerrod S. Scarborough, Marcus M. Maddox, Victoria Jones, Anna Grzegorzewicz, Lei Yang, Tamara Hess, Christophe Morisseau, Mary Jackson, Michael R. McNeil, Richard E. Lee, Design, synthesis and anti-tuberculosis activity of adamantyl heteroaryl ureas with improved in vitro and in vivo pharmacokinetic properties
  21(9), p. 2587-2599 2013
• Bioorganic & Medicinal Chemistry
  Michael S. Scherman, Elton J. North, Victoria Jones, Tammara N. Hess, Anna E. Grzegorzewicz, Takeo Kasagami, In-Hae Kim, Oleg Merzlikin, Anne J. Lenaerts, Richard E. Lee, Mary Jackson, Christophe Morisseau, and Michael R. McNeil, Screening a library of 1,600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability
  20(10), p. 3255-3262 2012
• Nature Chemical Biology
  Anna E. Grzegorzewicz, Ha Pham, Vijay Gundi, Michael S. Scherman, E. Jeffrey North, Tamara Hess, Victoria Jones, Veronica Gruppo, Sarah E. Born, J. Kordulakova, S. S. Chavadi, Christophe Morisseau, Anne J. Lenaerts, Richard E. Lee, Michael R. McNeil, Mary Jackson, Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane
  8(4), p. 334-341 2012
• Bioorganic & Medicinal Chemistry
  Joshua R. Brown, Elton J. North, Julian G. Hurdle, Christophe Morisseau, Jerrod S. Scarborough, Dianquing Sun, Jana Korduláková, Michael S. Scherman, Victoria Jones, Anna Grzegorzewicz, Rebecca M. Crew, Mary Jackson, Michael R. McNeil, Richard E. Lee, The Structure Activity Relationship of Urea Derivatives as Anti-Tuberculosis Agents
  19(18), p. 5585-5595 2011
• Journal of Medicinal Chemistry
  E. Jeffrey North, Angela L. Howard, Irene W. Wanjala, Truc Chi T. Pham, Daniel L. Baker, Abby L. Parrill, Pharmacophore Development and Application in Identifying Bioavailable Autotaxin Inhibitors
  53(8), p. 3095-3105 2010
• Bioorganic & Medicinal Chemistry
  E. Jeffrey North, Daniel A. Osborne, Peter K. Bridson, Daniel L. Baker, Abby L. Parrill, Autotaxin Structure-Activity Relationships Revealed through Lysophosphatidylcholine Analogs
  17(9), p. 3433-3442 2009
• Journal of Molecular Graphics & Modelling
  Truc-Chi T. Pham, James I. Fells Sr., Daniel A. Osborne, E. Jeffrey North, Mor M. Naor, Abby L. Parrill, Molecular recognition in the sphingosine 1-phosphate receptor family, Journal of Molecular Graphics and Modelling
  26(8), p. 1189-1201 2007

Presentations

• Design and Synthesis of Novel Oxadiazole-based Antimycobacterial Agents, Morgan Harris, Wei Li, Mary Jackson, E. Jeffrey North, Midyear Clinical Meeting and Exhibition, December 6-10, 2020. 2020
• E. J. North, Assessing Student Learning, Ensuring Integrity for Multiple Pathways in a Pharmacy Program, Midwestern University, August 3, 2020. 2020
• J. Sethiya, E. J. North, DISCOVERY OF NOVEL FADD32 INHIBITOR OF MYCOBACTERIUM TUBERCULOSIS WITH IMPROVED DRUG PROPERTIES, St. Alberts Day, Creighton University 2020
• R. Scott, L. Dieckman, E. J. North, Inhibitor Characterization for a Novel Ligase (FadD32) Essential for Mycobacterial Cell Wall Biosynthesis, St. Alberts Day, Creighton University 2020
• Discovery of Novel Oxamide-based Compounds As Anti-mycobacterial Agents, Brittney Kessel, E. Jeffrey North, Midwest Student Biomedical Research Forum, University of Nebraska Medical Center, February 27, 2020. 2020
• Design and synthesis of novel sulfonamides as anti-mycobacterial agents of the mycolic acid biosynthetic pathway, Jigar P. Sethiya, E. Jeffrey North, Midwest Student Biomedical Research Forum, University of Nebraska Medical Center, February 27, 2020. 2020
• P. Agrawal, K. S. Arte, E. J. North, J. A. Tolman, Improving global tuberculosis treatment through a novel inhaled drug-device combination product, Global Health Conference Midwest 2020, February 14-15, 2020. 2020
• "Design, Synthesis and Structure Activity Relationships of Adamantyl Ureas as Anti-tuberculosis Agents, " Spring 2013 Seminar Series, University of Memphis, Department of Chemistry, 2013
• "Design, Synthesis and Biological Assessment of Adamantyl Ureas as Anti-tuberculosis Agents with Improved Selectivity and Pharmacokinetic Factors," Gordon Research Conference, New Antibacterial Discovery & Development, Lucca (Barga), Italy, April 2012. 2012
• "Design Synthesis and Biological Evaluation of Adamantyl Ureas as Anti-tuberculosis Agents," Gordon Research Conference, TB Drug Development, Lucca (Barga), Italy 2011
• "Computer-guided Discovery of Autotaxin Inhibitors," 240th American Chemical Society National Meeting, Boston, Massachusetts. 2010

Foundation/Association

• Discovery of Novel Anti-Mycobacterium tuberculosis FadD32 Inhibitors, American Association of Colleges of Pharmacy, New Investigator Award

• Discovery and Development of Therapeutics to Treat Non-tuberculous Mycobacterial Infections.
  Sponsoring organization – Creighton University
  Awarding organization – Cystic Fibrosis Foundation
  Funding status – Funded
  Percent effort – 15%
  Other faculty involved – Dr. Mary Jackson (Colorado State University).Dr. Jackson is providing microbiological testing for compounds synthesized in my lab under the Cystic Fibrosis Foundation grant.
  This project’s first funding source was the Creighton University Health Sciences Strategic Investment Fund Faculty Development Grant awarded to Dr. North from July 2017 – June 2019 ($44,202).
  Dr. Dash, Dr. Hanson and I submitted an R15 in October 2020 and has recently been scored with an impact score of 20. Likely start date for this funding mechanism is July 1, 2021.

Other

• Discovery and Development of Therapeutics to Treat Non-tuberculous Mycobacterial Infections, Creighton University, Jack and Lois Wareham Research Award

• The Identification and Optimization of Novel Anti-tuberculosis Agents, Creighton University Office of Research and Compliance Services, LB 692

Awards

• Educator of the Year Award
  Distance Class of 2021
• Recipient of the 2018 Dr. Robert Heaney Graduate Research Mentor Award
  Creighton University
• Recipient of the 2017 Scholarly Achievement Award
  Creighton University
• Recipient of the 2017 Educator of the Year Award
  Pharmacy Campus Class 2019
• Recipient of the 2015 Educator of the Year Award
  Pharmacy Distance Class 2017

Consulting

• Consultant
  Consultant for Winthrop & Weinstine Law Firm helping to understand molecular descriptions and medicinal chemistry covered in drug/drug product patents.
  Winthrop & Weinstine Law Firm
  2016 - 2017